Calypte Names President and Chief Operating Officer to Ensure a More Efficient Transition into Its Marketing and Sales Phase
ALAMEDA, Calif.--(BUSINESS WIRE)--June 3, 2003--Calypte Biomedical Corporation (OTCBB:CYPTV - News), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced the appointment of Jay Oyakawa as president and chief operating officer. "Jay has the necessary vision, background, energy and the demonstrated ability to deliver the results that this position requires," said Anthony Cataldo, Executive Chairman of Calypte Biomedical. "We were fortunate that we were able to find exactly who we needed to move this company forward as we complete our restructuring."
Commenting on his new appointment, Mr. Oyakawa stated, "My number one priority is to transition this company into a sales and marketing mode. We have an excellent product, leading-edge technology, and the potential to capture a significant share of the HIV testing market, particularly given that Calypte expects its urine-based rapid screening test to enter international markets within the next several months. Now that the federal government has given AIDS the priority it deserves, we fully intend to take advantage of our FDA-approved urine-based HIV-1 antibody test in order to become a significant player in the global marketplace."
Mr. Oyakawa has over 11 years of sales management experience, and previously held senior management positions in Los Angeles-based TechProdX, and NameSafe Inc., and a management position at Donaldson Lufkin & Jenrette Securities. Mr. Oyakawa earned his bachelor's degree in Economics at UCLA, and his MBA in Finance and Health Care at The Wharton School, University of Pennsylvania.
About Calypte Biomedical:
|
Thread abonnieren
